Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
RLAY on Nasdaq
Shares outstanding
173,380,987
Price per share
$7.60
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
173,539,662
Total reported value
$1,468,044,711
% of total 13F portfolios
0%
Share change
+2,828,749
Value change
+$54,929,330
Number of holders
223
Price from insider filings
$7.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 9.9% +26% $88,740,000 +$19,053,000 17,000,000 +27% Commodore Capital LP 30 Sep 2025
Point72 Asset Management, L.P. 7.8% +35% $50,152,476 +$13,993,047 13,445,704 +39% Point72 Asset Management, L.P. 30 Jun 2025
Casdin Capital, LLC 7.5% $110,010,236 13,003,574 CASDIN CAPITAL, LLC 31 Dec 2025
BlackRock, Inc. 6.1% -30% $32,882,558 -$13,928,338 10,308,012 -30% BlackRock, Inc. 31 Mar 2025
VANGUARD GROUP INC 5.5% -24% $32,454,284 -$9,430,469 9,379,851 -23% The Vanguard Group 30 Jun 2025

As of 31 Dec 2025, 223 institutional investors reported holding 173,539,662 shares of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY). This represents 100% of the company’s total 173,380,987 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) together control 84% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
SB INVESTMENT ADVISERS (UK) LTD 16% 27,904,963 0% 2.4% $236,075,987
Commodore Capital LP 9.8% 17,000,000 0% 9.6% $143,820,000
Point72 Asset Management, L.P. 8% 13,859,172 -6.2% 0.18% $117,248,595
BlackRock, Inc. 7.6% 13,228,502 -3.9% 0% $111,913,127
Casdin Capital, LLC 7.5% 13,003,574 +15% 6.8% $110,010,236
VANGUARD GROUP INC 5.6% 9,691,445 +3.1% 0% $81,989,624
Bellevue Group AG 4.8% 8,345,364 -0% 1.3% $70,601,779
STATE STREET CORP 3.7% 6,426,111 +27% 0% $54,364,899
Nextech Invest, Ltd. 2.7% 4,701,506 +22% 3.8% $39,774,741
GEODE CAPITAL MANAGEMENT, LLC 2% 3,409,363 +12% 0% $28,849,082
TCG Crossover Management, LLC 1.9% 3,220,186 +78% 0.9% $27,242,774
Spruce Street Capital LP 1.7% 2,984,125 0% 8.3% $25,245,698
DIMENSIONAL FUND ADVISORS LP 1.4% 2,480,350 -0.1% 0% $20,983,096
MPM BIOIMPACT LLC 1.3% 2,232,451 -2.2% 2.2% $18,886,535
Balyasny Asset Management L.P. 1.2% 2,099,912 +79% 0.03% $17,765,256
MORGAN STANLEY 1.2% 2,018,464 +14% 0% $17,076,206
PERCEPTIVE ADVISORS LLC 1.1% 1,903,245 0.29% $16,101,453
GOLDMAN SACHS GROUP INC 1.1% 1,859,634 -0.49% 0% $15,732,503
PRICE T ROWE ASSOCIATES INC /MD/ 0.95% 1,645,403 +45% 0% $13,921,000
Alphabet Inc. 0.9% 1,568,753 0% 0.51% $13,271,651
TWO SIGMA INVESTMENTS, LP 0.9% 1,560,265 +42% 0.02% $13,199,842
Kynam Capital Management, LP 0.82% 1,424,259 -51% 0.78% $12,049,231
TWO SIGMA ADVISERS, LP 0.74% 1,289,800 +15% 0.02% $10,911,708
AQR CAPITAL MANAGEMENT LLC 0.67% 1,163,124 -11% 0.01% $9,840,028
BAKER BROS. ADVISORS LP 0.67% 1,160,117 0% 0.06% $9,814,590

Institutional Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.001 per share (RLAY) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 173,539,662 $1,468,044,711 +$54,929,330 $8.46 223
2025 Q3 166,220,789 $867,505,943 -$18,699,881 $5.22 196
2025 Q2 170,927,354 $591,366,333 +$36,190,035 $3.46 203
2025 Q1 162,665,545 $426,190,863 -$16,276,230 $2.62 205
2024 Q4 163,889,986 $675,297,060 -$42,360,167 $4.12 197
2024 Q3 163,415,012 $1,156,675,796 +$253,277,512 $7.08 193
2024 Q2 126,697,163 $826,050,230 -$42,426,305 $6.52 171
2024 Q1 132,236,260 $1,097,561,545 +$24,572,655 $8.30 182
2023 Q4 127,244,702 $1,400,985,578 -$17,110,979 $11.01 176
2023 Q3 130,456,510 $1,097,122,997 -$2,918,566 $8.41 169
2023 Q2 129,294,786 $1,623,964,520 -$20,848,790 $12.56 159
2023 Q1 131,039,866 $2,156,444,291 +$53,163,179 $16.47 155
2022 Q4 128,192,171 $1,915,159,649 +$58,936,160 $14.94 163
2022 Q3 123,551,085 $2,763,964,560 +$25,518,843 $22.37 153
2022 Q2 120,596,011 $2,019,993,086 +$124,571,798 $16.75 137
2022 Q1 113,095,261 $3,384,210,971 +$67,735,824 $29.93 133
2021 Q4 110,982,949 $3,407,692,692 +$588,792,014 $30.71 128
2021 Q3 91,778,622 $2,894,965,132 +$74,331,777 $31.53 132
2021 Q2 89,144,608 $3,261,742,353 +$138,052,473 $36.59 124
2021 Q1 85,493,244 $2,955,555,198 -$171,240,328 $34.57 135
2020 Q4 87,701,562 $3,644,892,889 +$108,159,345 $41.56 115
2020 Q3 84,683,348 $3,603,495,710 +$3,603,495,710 $42.59 94